Antiviral heterocyclic compounds
Inventors
Szymaniak, Adam • Leon, Robert • McGrath, Kevin • LI, XIBEN • Mann, Tyler J. • Yu, Jianming • Kim, In Jong • Mitchell, Scott • Or, Yat Sun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Core Innovation
The disclosed invention provides compounds represented by Formula (I), associated structural scaffold embodiments, table-listed compounds, and pharmaceutically acceptable salts thereof. The compounds comprise heteroaryl-substituted furo[2,3-c]pyridine carboxamides bearing amino alcohol side chains and chiral hydroxyl-containing scaffolds with defined substituents A, E, and R1 through R4. The claim defines A and E as optionally substituted aryl or heteroaryl, R3 as hydroxy or fluorine, and R4 as optionally substituted aryl, arylalkyl, heteroaryl, or heteroarylalkyl.
The compounds act as inhibitors of HRSV and HMPV, supported by reported antiviral activity against RSV-A and hMPV A2, and alternative synthesis of target compounds is detailed wherein [procedural detail omitted for safety]. Formulations include pharmaceutical compositions for intranasal and intrabronchial delivery for prevention or treatment of RSV and HMPV infections, including combination therapies with anti-inflammatory or anti-influenza agents. Because the abstract, summary, and background sections are omitted from the provided content, the problem being solved is not explicitly described in patent.
Claims Coverage
The claims identify two independent claims directed to two inventive features: a defined Formula (I) compound genus and table-listed compounds, including pharmaceutically acceptable salts.
Formula (I) compounds and pharmaceutically acceptable salts
A compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein A and E are each selected from optionally substituted aryl and optionally substituted heteroaryl; R1 and R2 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or are taken together with the nitrogen atom to form an optionally substituted 3- to 8-membered heterocyclic ring; R3 is hydroxy or fluorine; and R4 is selected from optionally substituted aryl, arylalkyl, heteroaryl, and heteroarylalkyl.
Table-listed compounds and pharmaceutically acceptable salts
A compound selected from the compounds set forth in the table, or a pharmaceutically acceptable salt thereof.
The independent claims cover the Formula (I) compound genus and specifically enumerated table-listed compounds, including pharmaceutically acceptable salts, with dependent claims covering pharmaceutical compositions and uses for RSV, influenza, and HMPV infections.
Stated Advantages
For similar prophylactic results, an additional anti-RSV agent can be administered at a lower dose or frequency than when administered alone.
The provided examples report antiviral activity against RSV-A, where most listed compounds have EC50 values below 0.2 ̂̂́̀M, and Examples 504 and 505 are rated active.
Documented Applications
Prevention or treatment of RSV infection using Formula (I) compounds, including prophylaxis wherein an additional anti-RSV agent is administered at a lower dose or frequency than when administered alone, or in combination with anti-inflammatory agents.
Treatment of concomitant RSV infection and influenza using a Formula (I) compound in combination with an anti-influenza agent.
Treatment or prevention of HMPV infection using a Formula (I) compound or combination of compounds.
Pharmaceutical compositions comprising a Formula (I) compound or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, diluent, or excipient, including intranasal and intrabronchial delivery forms.
Interested in licensing this patent?